These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
518 related articles for article (PubMed ID: 32302411)
1. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19. Damle B; Vourvahis M; Wang E; Leaney J; Corrigan B Clin Pharmacol Ther; 2020 Aug; 108(2):201-211. PubMed ID: 32302411 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection. Nicol MR; Joshi A; Rizk ML; Sabato PE; Savic RM; Wesche D; Zheng JH; Cook J Clin Pharmacol Ther; 2020 Dec; 108(6):1135-1149. PubMed ID: 32687630 [TBL] [Abstract][Full Text] [Related]
3. Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity. Hache G; Rolain JM; Gautret P; Deharo JC; Brouqui P; Raoult D; Honoré S Microb Drug Resist; 2021 Mar; 27(3):281-290. PubMed ID: 33729874 [TBL] [Abstract][Full Text] [Related]
4. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal. Fantini J; Chahinian H; Yahi N Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32862840 [TBL] [Abstract][Full Text] [Related]
5. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial. Sivapalan P; Ulrik CS; Bojesen RD; Lapperre TS; Eklöf JV; Håkansson KEJ; Browatzki A; Tidemansen C; Wilcke JT; Janner J; Gottlieb V; Meteran H; Porsbjerg C; Madsen BL; Moberg M; Pedersen L; Benfield TL; Lundgren JD; Knop FK; Biering-Sørensen T; Ghanizada M; Sonne TP; Bødtger UCS; Jensen SG; Rasmussen DB; Brøndum E; Tupper OD; Sørensen SW; Alstrup G; Laursen CB; Møller UW; Sverrild A; Jensen JS Trials; 2020 Jun; 21(1):513. PubMed ID: 32522282 [TBL] [Abstract][Full Text] [Related]
6. Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling. Rowland Yeo K; Zhang M; Pan X; Ban Ke A; Jones HM; Wesche D; Almond LM Clin Pharmacol Ther; 2020 Nov; 108(5):976-984. PubMed ID: 32531808 [TBL] [Abstract][Full Text] [Related]
7. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine. de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793 [TBL] [Abstract][Full Text] [Related]
8. Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis. Risch HA Am J Epidemiol; 2020 Nov; 189(11):1218-1226. PubMed ID: 32458969 [TBL] [Abstract][Full Text] [Related]
9. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306 [TBL] [Abstract][Full Text] [Related]
10. Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin. Derendorf H Int J Antimicrob Agents; 2020 Jun; 55(6):106007. PubMed ID: 32389720 [TBL] [Abstract][Full Text] [Related]
11. Chloroquine and hydroxychloroquine provoke arrhythmias at concentrations higher than those clinically used to treat COVID-19: A simulation study. Okada JI; Yoshinaga T; Washio T; Sawada K; Sugiura S; Hisada T Clin Transl Sci; 2021 May; 14(3):1092-1100. PubMed ID: 33404133 [TBL] [Abstract][Full Text] [Related]
12. Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials. Chi G; Memar Montazerin S; Lee JJ; Kazmi SHA; Shojaei F; Fitzgerald C; Gibson CM J Med Virol; 2021 Dec; 93(12):6737-6749. PubMed ID: 34370328 [TBL] [Abstract][Full Text] [Related]
13. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Maisonnasse P; Guedj J; Contreras V; Behillil S; Solas C; Marlin R; Naninck T; Pizzorno A; Lemaitre J; Gonçalves A; Kahlaoui N; Terrier O; Fang RHT; Enouf V; Dereuddre-Bosquet N; Brisebarre A; Touret F; Chapon C; Hoen B; Lina B; Calatrava MR; van der Werf S; de Lamballerie X; Le Grand R Nature; 2020 Sep; 585(7826):584-587. PubMed ID: 32698191 [TBL] [Abstract][Full Text] [Related]
14. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Furtado RHM; Berwanger O; Fonseca HA; Corrêa TD; Ferraz LR; Lapa MG; Zampieri FG; Veiga VC; Azevedo LCP; Rosa RG; Lopes RD; Avezum A; Manoel ALO; Piza FMT; Martins PA; Lisboa TC; Pereira AJ; Olivato GB; Dantas VCS; Milan EP; Gebara OCE; Amazonas RB; Oliveira MB; Soares RVP; Moia DDF; Piano LPA; Castilho K; Momesso RGRAP; Schettino GPP; Rizzo LV; Neto AS; Machado FR; Cavalcanti AB; Lancet; 2020 Oct; 396(10256):959-967. PubMed ID: 32896292 [TBL] [Abstract][Full Text] [Related]
15. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Yao X; Ye F; Zhang M; Cui C; Huang B; Niu P; Liu X; Zhao L; Dong E; Song C; Zhan S; Lu R; Li H; Tan W; Liu D Clin Infect Dis; 2020 Jul; 71(15):732-739. PubMed ID: 32150618 [TBL] [Abstract][Full Text] [Related]
16. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial. Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363 [TBL] [Abstract][Full Text] [Related]
17. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). Shah S; Das S; Jain A; Misra DP; Negi VS Int J Rheum Dis; 2020 May; 23(5):613-619. PubMed ID: 32281213 [TBL] [Abstract][Full Text] [Related]
18. Chloroquine and its derivatives in the management of COVID-19: A scoping review. Pimentel J; Andersson N Biomedica; 2020 Oct; 40(Supl. 2):80-95. PubMed ID: 33152192 [TBL] [Abstract][Full Text] [Related]
19. Assessment of Recovery Time, Worsening, and Death among Inpatients and Outpatients with COVID-19, Treated with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso. Rouamba T; Ouédraogo E; Barry H; Yaméogo NV; Sondo A; Boly R; Zoungrana J; Ouédraogo AR; Tahita MC; Poda A; Diendéré AE; Ouedraogo AS; Valea I; Traoré I; Tarnagda Z; Drabo MK; Tinto H; Int J Infect Dis; 2022 May; 118():224-229. PubMed ID: 35227869 [TBL] [Abstract][Full Text] [Related]
20. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Sargiacomo C; Sotgia F; Lisanti MP Aging (Albany NY); 2020 Mar; 12(8):6511-6517. PubMed ID: 32229706 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]